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Abstract
Tumor protein phosphorylation analysis may provide insight into intracellular signaling networks 
underlying tumor behavior, revealing diagnostic, prognostic or therapeutic information. Human 
tumors collected by The Cancer Genome Atlas (TCGA) program potentially offer the opportunity 
to characterize activated networks driving tumor progression, in parallel with the genetic and 
transcriptional landscape already documented for these tumors. However, a critical question is 
whether cellular signaling networks can be reliably analyzed in surgical specimens, where freezing 
delays and spatial sampling disparities may potentially obscure physiological signaling. To 
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quantify the extent of these effects, we analyzed the stability of phosphotyrosine (pTyr) sites in 
ovarian and colon tumors collected under conditions of controlled ischemia and in the context of 
defined intratumoral sampling. Cold-ischemia produced a rapid, unpredictable, and widespread 
impact on tumor pTyr networks within 5 minutes of resection, altering up to 50% of pTyr sites by 
more than 2-fold. Effects on adhesion and migration, inflammatory response, proliferation, and 
stress response pathways were recapitulated in both ovarian and colon tumors. Additionally, 
sampling of spatially distinct colon tumor biopsies revealed pTyr differences as dramatic as those 
associated with ischemic times, despite uniform protein expression profiles. Moreover, intra-
tumoral spatial heterogeneity and pTyr dynamic response to ischemia varied dramatically between 
tumors collected from different patients. Overall, these findings reveal unforeseen phosphorylation 
complexity, thereby increasing the difficulty of extracting physiologically relevant pTyr signaling 
networks from archived tissue specimens.In light of this data, prospective tumor pTyr analysis will 
require appropriate sampling and collection protocols to preserve in vivo signaling features.
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Introduction
Protein post-translational modifications (PTMs), such as phosphorylation, regulate the 
stability, localization, and activity of cellular components (1-3). Accordingly, dynamic 
phosphorylation plays a vital role in coordinating information flow within the cell and 
regulating emergent tumor responses ranging from proliferation to invasion and 
angiogenesis. Phosphorylation occurs predominantly on serine and threonine residues with 
tyrosine phosphorylation accounting for only ∼0.05% of all phosphorylation events in 
eukaryotic cells (4). Although tyrosine phosphorylation is rare and tyrosine kinases 
represent only 0.3% of the genome, these enzymes represent close to 30% of the known 
oncoproteins such as SRC, EGFR, and BCR-ABL (5). Their disproportionate role in 
oncology, combined with their structural druggability, make tyrosine kinases highly 
desirable therapeutic targets. Quantitative analysis of protein tyrosine phosphorylation in 
human tumor tissue specimens can provide insight into intracellular signaling networks 
underlying tumor behavior while identifying activated kinases and their substrates, signaling 
components that may represent druggable targets.
Human tumors collected by The Cancer Genome Atlas (TCGA) program potentially offer 
the opportunity to characterize activated signaling networks driving tumor progression, in 
parallel with the genetic and transcriptional landscape already documented for these tumors 
(6-8). The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (NCI-
CPTAC) seeks to provide proteomic characterization of tumors genomically annotated by 
TCGA programs (9). State-of-the-art mass spectrometry (MS)-based proteomics provides 
quantitative, systematic analysis of protein phosphorylation profiles (10-12) with the 
potential to directly identify activated signaling networks in tumors; information that is 
difficult to derive from genetic based studies. However, tumor specimen analysis is 
complicated by possible temporal delays in tissue acquisition and processing along with 
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spatial sampling differences due to the heterogeneous nature of human tumors. Freezing 
delays following sample resection and processing subject the specimen to ischemia; 
unfortunately the exact time to freezing for archived tissue specimens is often 
undocumented. To date, studies on the effects of ischemia on tissue phosphorylation have 
been reported, yet the sample collection and analysis approaches used did not allow 
assessment of short periods of ischemia (13) or permit comprehensive analysis of pTyr 
signaling (14).
The heterogeneous nature of human tumors has been widely documented (15,16). Inter-
patient and intra-tumoral variations are evident at a macroscopic histological level and at 
molecular, genetic, and epigenetic levels through clonal evolution and tumor 
microenvironment influences (17,18). A previous report investigated phosphorylation 
patterns across distinct anatomic metastatic lesions of prostate cancer. However, the number 
of phosphorylation sites profiled was limited and intra-lesion comparison was not performed 
(19).The influence of proximal spatial heterogeneity within a tumor specimen on pTyr 
signaling networks has yet to be determined. Collectively, these pre-analytical factors may 
influence protein phosphorylation measurements, thereby obscuring physiological signaling 
networks (20). Therefore, we sought to investigate how pre-analytical variations in sample 
collection and processing can ultimately affect downstream pTyr signaling analysis of 
human tumors.
Materials and Methods
Human ovarian and colon tumor collection
High-grade serous ovarian carcinoma tissue from five patients was collected as previously 
reported (21). Colon adeno carcinoma biopsy tissue was collected from five patients at the 
Cooperative Human Tissue Network at Vanderbilt University Medical Centre (CHTN-
VUMC), in accordance with IRB-approved protocols. Following vessel ligation, surgical 
specimen removal was performed and the first core biopsy was taken immediately thereafter 
(t=0), transferred to prechilled cryovials and snap frozen in liquid nitrogen. Further core 
biopsies were collected and frozen after 10, 30, and 60 minutes of cold ischemia. Only 
specimens meeting pathology quality inclusion criteria of left sided colon adenocarcinoma 
cancers in which clamp time can easily be determined, minimal tumor diameter of 4 cm and 
no prior chemotherapy and/or radiation were released for analysis.
Protein extraction, digestion, and iTRAQ labeling of peptides from ovarian and colon 
tumors
Approximately 50-100 mg (total wet weight) of each of the timepoint samples was 
homogenized separately for protein extraction and digestion as described previously (22). 
Desalted peptides were labeled with multiplex iTRAQ (Isobaric Tags for Relative and 
Absolute Quantification) reagents as reported previously (22). Briefly, 800 μg peptide per 
sample for each of the ovarian and colon tumor timepoints was labeled with two tubes of 
iTRAQ reagent (according to the labeling scheme shown in Supplementary Fig. 2 and 5).
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Phosphotyrosine peptide enrichment
Phosphotyrosine peptides were enriched prior to mass spectrometry analyses using a 
cocktail of anti-phosphotyrosine antibodies followed by immobilized metal affinity 
chromatography (IMAC) as previously described (22).
Mass-spectrometry based phosphotyrosine analysis
Peptides were chromatographically separated and subsequently analyzed by Orbitrap Elite 
mass spectrometer (Thermo Scientific), database-searched, validated and normalized as 
previously reported (22).
Phosphotyrosine data analysis
The total list of peptides and proteins identified and quantified can be found in 
Supplementary Table 1, 2 and 4. All mass spectra, in the original instrument vendor format, 
contributing to this study may be downloaded from: https://cptac-data-
portal.georgetown.edu/cptacPublic/
Mass-spectrometry based protein expression analysis
Approximately 10% (∼300 μg) of iTRAQ labeled peptides from each colorectal tumor pTyr 
IP supernatant was separated off-line on C18 column. A total of 80 fractions were collected, 
non-contiguously pooled into 20 final fractions, and each subjected to an independent LC-
MS/MS analysis. Each fraction was separated by reverse phase UHPLC (Easy-nLC 1000, 
Thermo Scientific) before nanoelectrospray directly into a Q-Exactive mass spectrometer 
(Thermo Scientific).
Protein expression data analysis
Peptide and protein identification were performed with the Proteome Discoverer software 
(version 1.4; Thermo Scientific) using Mascot search engine (version 2.4.1, Matrix Science). 
MS/MS spectra were searched against a human protein sequence database (NCBInr, 2012 
release, 35,586 sequences). For each protein expression experiment, one combined database 
search was performed where the data files from all 20 independent MS fraction analyses 
were searched collectively as a single input dataset. The total list of peptides and proteins 
identified and quantified can be found in Supplementary Table 5.
Affinity propagation clustering analysis
Quantitative temporal profiles of all pTyr sites within an individual patient dataset were 
clustered using the affinity propagation algorithm proposed by Frey and Dueck (23). 
Individual patient datasets were subjected to independent analysis (see Supplementary Fig. 
4) as described previously (22).
Statistical Analysis and Annotation
Hierarchical clustering analysis and heatmap construction was performed using the built-in 
Bioinformatics Toolbox function ‘Clustergram’ in Matlab (R2013b, The Mathworks Inc.) 
with Euclidean pairwise distance metric. Statistical analysis was conducted using GraphPad 
Prism 5.0a software. Pearson correlation analysis (two-tailed), and pairwise Student t tests 
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(two-tailed) were used for calculating the significance of the differences and significance 
was accepted when P < 0.05. Kinase enrichment analysis was performed using the webtool 
at http://amp.pharm.mssm.edu/lib/kea.jsp and conducted as described previously (24). The 
input dataset was compiled from the union of ischemia-regulated pTyr sites found in ≥4 
ovarian tumor samples and ≥4colon tumor samples. Predicted kinases were plotted onto a 
dendrogram of the human kinome (25) using the webtool at http://web.cecs.pdx.edu/
∼josephl/kinome-cluster/. Panther Gene ontology (GO) annotations were identified by 
uploading UniProt ID lists to the Protein Analysis Through Evolutionary Relationships 
(PANTHER) classification system (http://www.pantherdb.org/).
Results
Post-excision ischemia induces rapid, widespread, patient-dependent alterations to pTyr 
networks
Post-resection ischemia time is generally undocumented in TCGA samples but may range 
from minutes to an hour during processing and pathological inspection. To understand the 
effect of cold-ischemia on protein tyrosine phosphorylation, we collected patient-derived 
ovarian tumor samples from five individuals undergoing debulking surgery and performed a 
controlled ischemia 4-point time-course (Supplementary Fig. 2). Ischemia time course sets 
from each patient were analyzed separately, providing detection and quantitation of several 
hundred pTyr sites per patient (Supplementary Table 1). Within 5 minutes of cold-ischemia, 
the fraction of pTyr sites within a specimen that showed quantitative fluctuations ranged 
from 29-55%, depending on the patient (Fig. 1a and Supplementary Table 1). Intriguingly, 
the temporal response to ischemia was patient specific. Two patients, 39 and 67, showed a 
predominant decrease across many pTyr sites within the first five minutes, while the other 
patients had a more mixed response, with comparable proportions of increasing and 
decreasing sites. We hypothesized that some of the inter-patient differences in response to 
ischemia could be attributed to patient-specific baseline phosphorylation profiles. To 
investigate this possibility, the ‘0 min’ samples from each ovarian patient were analyzed 
simultaneously by quantitative multiplex MS, allowing the relative levels of each pTyr site 
at resection to be directly compared between patients. Euclidean distance hierarchical 
clustering indicated variation in the basal pTyr profiles of each patient, suggestive of distinct 
phosphorylation network states at excision (Fig. 1b, Supplementary Table 2).This result 
agrees with previous reports noting that tumors with similar driver mutations can 
demonstrate distinct signaling network profiles (22,26). Integration of the ischemia time-
course datasets with the inter-patient basal resection profile dataset revealed dependencies of 
ischemic response dynamics on initial baseline phosphorylation (Supplementary Table 2). 
For example, in the ERK1 activation loop the initial basal values were comparable, but the 
magnitude of change with ischemia time was distinct for different patients (Fig. 1c and 
Supplementary Fig. 3). For other sites, such as the activating site on STAT5A, the extent of 
ischemic regulation was dependent on the pTyr abundance at resection (Fig. 1d and 
Supplementary Fig. 3). These data suggest that documentation of the temporal delay 
between resection and freezing might not be sufficient to back-calculate the basal 
phosphorylation status prior to ischemia, since the dynamics for some phosphosites are 
patient specific.
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To identify systemic response to ischemia, affinity propagation analysis (23) was used to 
classify distinct clusters of pTyr sites with comparable temporal trends. Interestingly, several 
clusters behaved in a similar manner across patients, suggesting a set of co-regulated 
signaling responses to ischemia (Supplementary Fig. 4 and Supplemental Table 3). One 
cluster characterized by rapid increase in phosphorylation within 5 minutes of cold-ischemia 
included MAPK12, MAPK13, MAPK14, SHC1, GAB1, and SHIP (Fig. 1e, left). These 
acute responders to ischemia agree with the known roles of these proteins in stress responses 
and MAPK signaling (27-30). A separate cluster of pTyr sites whose phosphorylation 
decreased with increasing ischemia time included ephrin receptors, tensins, and 
plakophilins. These phosphoproteins are suggestive of modulation of cell adhesion, 
cytoskeletal, and migration related processes, all consistent with perfusion stress (Fig. 1e, 
right)(31-33). Other clusters include pTyr sites with minimal quantitative fluctuations, as 
well as sites with bi-directional regulation during the course of 60 minute cold-ischemia 
(Fig. 1e, middle). A‘core’ ischemia-regulated phosphorylation signature containing twenty-
two phosphorylation sites was detected across all ovarian tumor specimens. We devised a 
quantitative ‘ischemia-index’ to compare the relative severity of ischemia response among 
this consensus set. This signature represents four broad functional categories: adhesion and 
migration, inflammatory response, proliferation, and stress response (Fig. 1f). Given the 
primary importance of these pathways in tumor biology, delayed-freezing artifacts will 
likely create erroneous biological interpretations if tumor specimens intended for pTyr 
analysis are not immediately frozen.
Spatial phosphorylation heterogeneity is apparent in human tumor samples
The heterogeneous nature of human tumors has been described (15-18). However, the 
effects of inter-tumor spatial heterogeneity on cellular signaling networks are unknown. To 
understand the impact of spatially resolved samples on protein phosphorylation profiles, we 
analyzed the pTyr profiles of paired spatially distinct primary colorectal tumor samples from 
five individuals undergoing resection (Supplementary Fig. 5, and Supplementary Table 4). 
As with the ovarian tumors, a controlled ischemia time-course enabled analysis of pTyr 
dynamics and the generality of ischemia effects across tumors. Unsupervised hierarchical 
clustering of intratumoral paired-timepoint samples indicated the presence of pTyr 
heterogeneity in spatially proximal samples (Fig. 2a), as indicated by the greater difference 
in the paired time-point samples (i.e., 0a and 0b) compared to the non-paired points (i.e., 0b 
and 10a in patient 041). In patients 323 and 745, where the 0 min paired-timepoints 
clustered together, significant differences were still apparent. Technical measurement error 
did not contribute significantly to the observed variation, and was not the cause of the 
observed heterogeneity (Supplementary Fig. 6).Pearson correlation analysis of the 
quantitative pTyr data for each pair of time points (Supplementary Fig. 7) indicated weak 
correlations and minimal shared covariance between spatially proximal samples, even in 
tumor 323, the most ‘homogeneous’ tumor, where paired samples appear to cluster (Fig. 2b). 
Spatial heterogeneity has the potential to impact clinical decisions, as clinically diagnostic 
pTyr markers were statistically different in proximal regions at resection (Fig. 2c, 0 min 
pairs), in some cases by more than 2-fold. Freezing delays can further alter phosphorylation 
heterogeneity, as paired timepoints often provided different signaling profiles (Fig. 2c; 10, 
30, 60 min pairs).
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Spatial and temporal protein expression differences are minimal in tumor samples
To evaluate whether intra-tumor protein expression heterogeneity contributed to the 
observed spatial and temporal pTyr differences, we performed protein expression analysis of 
the colorectal specimens (Supplementary Fig. 8, Supplementary Table 5). Unsupervised 
hierarchical clustering indicated that protein expression is mostly uniform temporally and 
spatially (Fig. 3a).Where quantitative protein expression differences were observed between 
paired timepoints, they were muted compared to the large differences identified in pTyr 
profiles. To systematically evaluate the relationship between protein expression 
heterogeneity and pTyr levels, we identified 76 pTyr sites where corresponding protein 
levels were also available (Fig. 3b, Supplementary Table 6). Whereas protein expression 
was invariant with both spatial location and ischemia, pTyr levels showed dramatic spatial 
and ischemic time-dependent variation. These results suggest that differential ischemic 
responses could occur in adjacent parts of a tumor. For example, selected pTyr sites in 
patient 041 exhibited spatially distinct changes during ischemia, despite uniform expression 
of the corresponding proteins (Fig. 3c).
Ischemia alterations occur across tumor types impacting a core set of functional classes 
yet has the potential to affect biologically diverse pTyr pathways
To reduce the impact of spatial heterogeneity on phosphorylation and identify consistent 
ischemia-related changes, we averaged the pTyr measurements from paired-timepoint 
samples. As with the ovarian tumors, a large proportion of pTyr sites showed significant 
quantitative changes following delayed freezing (Fig. 4a, Supplementary Table 4). These 
results demonstrate that delayed-freezing effects can alter tyrosine phosphorylation in 
multiple tumor types. As with the ovarian cancer samples, inter-patient differences were 
observed for temporal dynamics (Supplementary Table 4). From these data, we extracted a 
minimal ischemia-regulated signature of 12 pTyr sites common to both ovarian and 
colorectal samples; adhesion and migration, proliferation, and stress response pathways are 
represented within this signature (Fig. 4b). Due to the inter-patient biological variation, 
many additional specimen-specific ischemia-driven pTyr perturbations were documented. 
Accordingly, when all tumor variation is considered it becomes apparent that extensive 
ischemia-dependent alterations affect most tyrosine kinases (Fig. 4c, Supplemental Table 7). 
The pathways impacted by ischemia encompass diverse kinases and downstream effectors 
across broad biological functions and processes (Supplementary Fig. 9). Therefore, 
ischemia, particularly of unknown duration, may distort pTyr network profiles to an extent 
that cannot be reliably corrected.
Discussion
There is a strong impetus to comprehensively integrate genetic profiles of tumors with 
corresponding proteomic expression and protein phosphorylation datasets (9).The salient 
findings of this study indicate that measurement of pTyr signaling nodes in human tumors is 
i) susceptible to extensive post-resection ischemia effects creating rapid and systemic 
changes that alter the initial in situ tumor phosphorylation profile, and ii) distinct intra-tumor 
phosphorylation profiles are apparent indicating spatial micro-heterogeneity, and 
presumably signaling differences, within specimens. Our findings suggest that the tumor 
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specimens are actively regulating signaling events despite their loss of blood supply and 
attachment to the surrounding tissue. Hypoxia, hypoglycemia, acidosis, hypothermia, and 
osmotic disturbances are perturbations to which the tumor acutely responds until 
cryopreservation. The immediate implication is that insight regarding tumor pTyr signaling 
in human tumor specimens may be greatly misleading or incorrect depending on the nature 
and duration of tumor harvesting/processing before analysis. Unfortunately, retrospective 
extrapolation of an accurate in vivo phosphorylation state appears to be prohibitively 
difficult due to unique dynamics on each pTyr site coupled with unpredictable patient 
specific responses to ischemia (Fig. 1c, d and Supplementary Fig. 3).
The temporal trends and directionality of pTyr fluctuation observed are consistent with the 
physiological effects of tumor resection and a step-wise signaling response. In fact, the pTyr 
sites within the identified temporal clusters appear to correlate with progressive stages of 
ischemic stress (Fig. 1e, Supplementary Fig. 4, and Supplementary Table 3). For example, 
physical stresses from wounding, hypoxia and osmotic shock result in the immediate 
activation of response pathways to promote tissue repair and regeneration. This activity is 
consistent with the observed rapid hyperphoshorylation of p38 MAPKs (ie. MAPK12, 
MAPK13, MAPK14) through oxidative stress-sensing ASK1 and osmosensing OSM 
(34,35). Activation of these pathways can in turn trigger signaling programs necessary for 
the production of pro-inflammatory cytokines and tissue repair (36). This immediate 
signaling cluster also included increased phosphorylation of mitogenic nodes on SHC1, 
GAB1, and MAPK1 and MAPK3 sites to potentially initiate proliferative regeneration. 
Sustained ischemia times were accompanied by more gradual cellular responses. Increased 
phosphorylation of PRKCD, a known substrate of a caspase-3 during apoptosis, was 
observed across all ovarian tumors. Lack of perfusion leads to cellular dehydration, 
shrinkage and distortion. Accordingly, phosphorylation decreases on EPHA2, EPHA4, 
EPHB2, PARD3, PKP4, and TNS3 agree with physiologic changes in loss of cell-cell and 
ECM contacts (31-33). Collectively, the directionality and timing of several phosphorylation 
sites are consistent with the physiologic stages of severe ischemia.
Of note, the core pTyr ischemia signature described overlaps with functional pathways 
known to be relevant in the signaling of cancer cells such as adhesion, migration, and 
proliferation (37,38). Importantly, in many cases the pTyr sites annotated are directly 
implicated in regulating protein function—for example 17 of 22 pTyr sites in the core 
ischemia signature (Fig. 1f) have been shown experimentally to directly modulate protein 
kinase activity and function. As such, these are not uncharacterized phosphorylation events 
but rather functionally relevant pTyr sites with probable signaling consequences. Moreover, 
while phosphorylation changes of greater than two-fold were detected during the ischemia 
timecourse (20-28% and 25-48% of peptides in ovarian and colon tumors respectively; 
Supplemental Table 2 and 4) and often used to prioritize biologically significant signaling 
changes, the magnitude of change does not always correlate with signaling significance. In 
fact, modest changes to phosphorylation levels may correspond to meaningful biological 
results as demonstrated in the context of MEK, K-RasG12D, or EGFRvIII, where slight 
changes to the signaling activity have profound effects on viability and oncogenicity 
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(39-41). As such, the subset of pTyr sites with seemingly insignificant variations may still in 
fact push signaling networks away from a fine-tuned steady state (42).
It is import to emphasize that the extensive list of ischemia-regulated pTyr sites in ovarian 
and colon tumors (Fig. 4c and Supplementary Fig. 9) spans a multitude of pathways and 
processes and are not limited to obvious stress response pathway proteins (ie. p38 MAPKs). 
While it is tempting to speculate that tumors with strong driver signaling (ie. HER2 
overexpression) could still generate pTyr signatures which overshadow ischemia induced 
signatures, this is conceptually unlikely for at least two reasons. First, oncogenic signaling 
mutations do not always exhibit enhanced levels of phosphorylation—but can instead 
present persistent, minor increases to achieve oncogenic network states(40,41). Secondly, 
strong pTyr signaling would likely impinge on the nodes and pathways affected by ischemia 
(ie. proliferation, migration, adhesion, etc.) preventing definite attribution of the source. 
Thus, it will not be feasible for future pTyr experiments to simply exclude a set of ‘ischemia 
susceptible’ proteins and derive a quantitatively reliable dataset since the boundaries of 
susceptible and stable pTyr sites are not entirely clear, appear to be patient specific and 
cannot be predicted a priori based on our current knowledge.
The use of surgically excised tumors in this study was paramount to recapitulate a typical 
biospecimen collection scenario, however an unexpected caveat of this analysis was the 
realization that pTyr tumor heterogeneity exists even on a relatively proximal scale. Spatial 
heterogeneity of tyrosine phosphorylation may have significant impact on clinical decisions. 
As alluded to in Figure 2c, monitoring of therapeutic efficacy in pre-clinical or clinical trials 
is often examined by measuring phosphorylation levels on kinases and other signaling 
targets. However, using pTyr as a diagnostic proxy in human specimens could pose 
challenging, as inadequate assessment of clinically relevant pTyr sites is possible depending 
on the extent of tumor spatial heterogeneity and breadth of sampling. Ideally, this variation 
should be acknowledged and accounted for in current and future studies to allow appropriate 
interpretation of pTyr levels in human tumor specimens (e.g. multiple, spatially distinct pre- 
and post-therapy biopsies when evaluating drug efficacy.) A concurrent CPTAC study of the 
ischemia-driven effects on serine/threonine phosphorylation in tumor samples revealed 
complementary insights (21). Although examination of the same ovarian tumor specimens 
used here suggested that serine/threonine phosphorylation might be less susceptible to 
ischemia, perturbations were observed in approximately 6% of the ∼9,000 pSer/pThr sites 
measured (based on those sites overlapping in at least 3 samples), with the majority of these 
sites concentrated in stress signaling pathways. This result is in contrast to this study, where 
perturbations were observed in 62% of 217 sites measured in ovarian tumors (based on those 
sites overlapping in at least 3 samples) and ∼44% of 57 sites measured across both ovarian 
and colon tumors (overlap in at least 3 samples). These differences are likely attributable to 
the highly regulated nature of pTyr sites compared to pSer/pThr sites, and may be indicative 
of the biological relevance of the regulated phosphorylation sites measured in both studies.
In summary, immediate freezing of human tumor specimens is necessary to minimize post-
resection artifacts that could confound identification of physiological pTyr signaling 
networks. Intra-tumoral phosphorylation heterogeneity suggests that performing single 
biopsies of primary tumors or metastases, as is usual clinical practice, may provide 
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erroneous or incomplete profiles of signaling systems in tumors. These data suggest that 
multiple biopsies, immediately flash-frozen, may be necessary to accurately assess the 
signaling characteristics of human tumors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Post-excision ischemia induces rapid, widespread, patient-dependent alterations to pTyr 
networks. (a) Heatmaps of all quantified peptides from individual patient-derived ovarian 
tumor 4-timepoint ischemia study. Rows indicate mass spectrometry-derived quantitative 
levels of pTyr sites in log2 scale relative to t=0 min, rank ordered by value at t=60 min. 
Onset of color in the heatmaps corresponds to changes ≥3 s.d. from value at t=0 (red, 
increasing; blue, decreasing). See Supplementary Table 1 for details. (b)Hierarchical-
clustered heatmap of quantitative pTyr profiles of individual ovarian tumors at resection. 
Quantitative levels of pTyr sites grouped in rows, in log2 mean normalized scale. (c, d) 
Select examples of distinct inter-patient ischemia regulated temporal dynamics. Colored 
lines represent relative inter-patient phosphorylation levels, mean ± s.d. of technical 
replicates is shown. Temporal data values shown are derived from independent patient 
datasets and normalized with t=0 value measured in b (See Supplementary Fig. 3 for 
additional examples). (e) Affinity propagation-derived clusters for pTyr sites detected in 
patient 27 (See Supplementary Fig. 4 for affinity propagation clusters of other patients). 
Subplots signify groups of pTyr sites with similar quantitative trends across time (x-axis). 
Solid lines denote trends of individual pTyr sites. Mean log2-temporal values relative to t=0 
min are shown. Exemplar pTyr site of each cluster shown in blue. (f) Ischemia-regulated 
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phosphorylation sites common to all patients with functional categorization. Ischemia index 
(y-axis) for each site represents absolute sum of the log2 changes relative to t=0 at5, 30, 60 
minutes. Mean value ± SEM from all patients is plotted. Asterisks denote sites known to be 
implicated in protein activity or function.
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Figure 2. 
Spatial phosphorylation heterogeneity is apparent in human colon tumors. (a) Separate 
unsupervised hierarchical-clustered heatmaps represent the spatial and temporal sample set 
of each patient-derived colon tumor. Patient identifier shown to top left of each heatmap. 
Rows indicate mass spectrometry-derived quantitative levels of pTyr sites in log2 mean 
normalized scale. Onset of saturated color in the heatmaps corresponds to changes ≥2-fold 
from the mean (red, increasing; blue, decreasing). (b) Pearson correlation analysis was used 
to quantify the direction and magnitude of correlation among the spatially distinct colorectal 
tumor samples. Data points presented in each plot are the log2mean-centered value for a 
given pTyr site between paired spatially-distinct samples at the indicated timepoints in 
patient 323. r=Pearson correlation coefficient; 95% CI= 95% confidence interval of r; 
P=two-tailed p-value. See Supplementary Fig. 7 for correlation analysis of other patients. (c) 
Phosphorylation levels of clinically useful pTyr sites are plotted for each patient spatial and 
temporal sample set. Samples are shaded according to patient and columns grouped to 
indicate identical timepoint samples that are spatially distinct. Mean value ± SEM is plotted. 
Statistically significant differences are indicated. Note: ** indicates P=0.001 to 0.01, and * 
indicates P=0.01 to 0.05.
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Figure 3. 
Spatial and temporal protein expression differences are minimal in colorectal tumors. 
(a)Separate unsupervised hierarchical-clustered heatmaps represent the spatial and temporal 
sample set of each patient-derived colon tumor. Patient identifier shown to top left of each 
heatmap. Rows indicate mass spectrometry-derived quantitative levels of protein expression 
in log2 mean normalized scale. Onset of saturated color in the heatmaps corresponds to 
changes ≥2-fold from the mean (red, increasing; blue, decreasing). (b) Quantitative levels of 
protein (from a) and matching pTyr sites (from 2a) on the same protein. Rows represent 
values in log2 scale relative to t=0a min. Onset of color in the heatmaps represents changes 
greater than ∼1.4-fold from the mean (red, increasing; blue, decreasing) to emphasize 
uniformity in protein expression values compared to pTyr values. Plotted pTyr values are 
also quantitatively normalized to the protein expression levels. See Supplementary Table 6 
for details. (c) Selected examples of corresponding protein and pTyr levels from b. Columns 
are shaded to group identical timepoint samples that are spatially distinct. Mean value ± 
SEM is plotted.
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Figure 4. 
Ischemia alterations occur across tumor types impacting a core set of functional classes yet 
has the potential to affect biologically diverse pTyr pathways. (a) Heatmaps of individual 
patient-derived colorectal tumor 4-timepoint ischemia study. Rows indicate mass 
spectrometry-derived quantitative levels of pTyr sites in log2 scale relative to t=0 min, rank 
ordered by value at t=60av min. Average value of paired timepoints is plotted. Onset of color 
in the heatmaps corresponds to changes ≥3 s.d. from value at t=0av (red, increasing; blue, 
decreasing). See Supplementary Table 4 for details. (b) Venn diagram indicating ischemia-
phosphorylation signature observed in multiple tumors. 56 ischemia-regulated sites were 
detected in ≥4 ovarian tumor samples and 29 ischemia-regulated sites were detected in ≥4 
colorectal tumor samples. (c) Kinase enrichment analysis (from union of data in b) was 
performed to identify kinases with high-confidence enrichment and plotted onto a map of 
the human kinome using Kinome Cluster to highlight the diverse set of kinases affected by 
delayed freezing. Green circle=kinases significantly altered in ≥4 colon tumors and/or ≥4 
ovarian tumors.
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